Psoriasis Vulgaris and Arthropathica

  • Jörg Christoph Prinz


Psoriasis vulgaris is an HLA-associated inflammatory disorder, which affects ~2% of the Caucasian population. It presents with a characteristic type of skin lesions which appear as sharply demarcated reddish plaques of variant size covered with intensive silvery scaling (Fig. 1). In a significant proportion of patients (> 10%), psoriasis also involves the joints, sometimes leading to severe arthritis.


Human Leukocyte Antigen Psoriatic Arthritis Neutrophilic Granulocyte Psoriatic Lesion Seborrheic Dermatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383: 787–793PubMedCrossRefGoogle Scholar
  2. Adam O (1995) Anti-inflammatory diet in rheumatic diseases. Eur J Clin Nutr 49: 703–71PubMedGoogle Scholar
  3. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Docke WD (1998) IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 101: 783–79PubMedCrossRefGoogle Scholar
  4. Baker BS, Powles AV, Malkani AK, Lewis H, Valdimarsson H, Fry L (1991) Altered cell-mediated immunity to group A haemolytic streptococcal antigens in chronic plaque psoriasis. Br J Dermatol 125: 38–42PubMedCrossRefGoogle Scholar
  5. Baker BS, Bolith S, Powles AV, Valdimarsson H, Fry L (1992) Streptococcal antigen-specific T lymphocytes in skin lesions of guttate psoriasis. J Invest Dermatol 98: 535–538Google Scholar
  6. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD (1995) Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 95: 317–3Google Scholar
  7. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH (1983) Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 275: 181–189Google Scholar
  8. Brandrup F, Holm N, Grunnet N, Henningsen K, Hansen HE (1982) Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol 62: 229–2PubMedGoogle Scholar
  9. Braun-Falco O, Christophers E (1974) Structural aspects of initial psoriatic lesions. Arch Dermatol Forsch 251: 95PubMedCrossRefGoogle Scholar
  10. Chang JCC, Smith LR, Froning KJ, Schwabe BJ, Laxer JA, Caralli LL, Kurland HH, Karasek MA, Wilkinson DI, Carlo DJ, Brostoff SW (1994) CD8` T cells in psoriatic lesions preferentially use T-cell receptor V133 and/or Vß13.1 genes. Proc Natl Acad Sci USA 91: 9282–9286PubMedCrossRefGoogle Scholar
  11. Chang JC, Smith LR, Froning KJ, Kurland HH, Schwabe BJ, Blumeyer KK, Karasek MA, Wilkinson DI, Farber EM, Carlo DJ, Brostoff SW (1997) Persistence of T-cell clones in psoriatic lesions. Arch Dermatol 133: 703–708PubMedCrossRefGoogle Scholar
  12. Dirckx JH (1983) Dermatologic terms in the De Medicina of Celsus. Am J Dermatopathol 5: 363–369PubMedCrossRefGoogle Scholar
  13. Edlund E, Johnsson U, Lidgren L, Pettersson H, Sturfelt G, Svensson B, Theander J, Willen H (1988) Palmoplantar pustulosis and sternocostoclavicular arthro-osteitis. Ann Rheum Dis 47: 809–81PubMedCrossRefGoogle Scholar
  14. Farber EM (1992) History of the treatment of psoriasis. J Am Acad Dermatol 27: 640–645PubMedCrossRefGoogle Scholar
  15. Farber EM, Nall ML, Watson W (1974) Natural history of psoriasis in 61 twin pairs. Arch Dermatol 109: 207–211PubMedCrossRefGoogle Scholar
  16. Fujinami RS, Oldstone MB (1985) Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230: 1043–1045PubMedCrossRefGoogle Scholar
  17. Glickman FS (1986) Lepra, psora, psoriasis. J Am Acad Dermatol 14: 863–866PubMedCrossRefGoogle Scholar
  18. Gordon M, Johnson WC (1967) Histopathology and histochemistry of psoriasis. I. The active lesion and clinically normal skin. Arch Dermatol 95: 402–407Google Scholar
  19. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG (1995) Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1: 442–447PubMedCrossRefGoogle Scholar
  20. Gudmundsdottir AS, Sigmundsdottir H, Sigurgeirsson B, Good MF, Valdimarsson H, Jonsdottir I (1999) Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Immunol 117: 580–586PubMedCrossRefGoogle Scholar
  21. Halpern SM, Anstey AV, Dawe RS, Diffey BL, Farr PM, Ferguson J, Hawk JL, Ibbotson S, McGregor JM, Murphy GM, Thomas SE, Rhodes LE (2000) Guidelines for topical PUVA: a report of a workshop of the British photodermatology group. Br J Dermatol 142: 22–31PubMedCrossRefGoogle Scholar
  22. Harder J, Bartels J, Christophers E, Schröder JM (1997) A peptide antibiotic from human skin. Nature 387: 861PubMedCrossRefGoogle Scholar
  23. Harvima IT, Naukkarinen A, Harvima RJ, Horsmanheimo M (1989) Enzyme-and immunohistochemical localization of mast cell tryptase in psoriatic skin. Arch Dermatol Res 281: 387–391PubMedCrossRefGoogle Scholar
  24. Henseler T (1998) Genetics of psoriasis. Arch Dermatol Res 290: 463–476PubMedCrossRefGoogle Scholar
  25. Jenisch S, Koch S, Henseler T, Nair RP, Elder JT, Watts CE, Westphal E, Voorhees JJ, Christophers E, Kronke M (1999) Corneodesmosin gene polymorphism demonstrates strong linkage disequilibrium with HLA and association with psoriasis vulgaris. Tissue Antigens 54: 439–449PubMedCrossRefGoogle Scholar
  26. Kägi MK, Wüthrich B, Montano E, Baladun J, Blaser K, Walker C (1994) Differenliaï cytokine profiles in peripheral blood lymphocyte supernatants and skin biopsies from patients with different forms of atopic dermatitis, psoriasis and normal individuals. Int Arch Allergy Immunol 103: 332–340PubMedCrossRefGoogle Scholar
  27. Koo J, Lebwohl M (1999) Duration of remission of psoriasis therapies. J Am Acad Dermatol 41: 51–5PubMedCrossRefGoogle Scholar
  28. Leach D, Beckwith J (1999) The founders of dermatology: Robert Willan and Thomas Bateman. J R Coll Physicians Lond 33: 580–58Google Scholar
  29. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, Shupack J, Weinstein G (1998) Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 39: 464–475PubMedCrossRefGoogle Scholar
  30. McCarty M (1973) Host-parasite relations in bacterial diseases. In: Microbiology ( Davis BD, Dulbecco R, Eisen HN, Ginsberg HS, Wood WB, McCarty M eds), pp 627–665. Hagerstown, New York, Evanstown, San Francisco, London: Harper & Row.Google Scholar
  31. Menssen A, Trommler P, Vollmer S, Schendel D, Albert E, Gürtler L, Riethmüller G, Prinz JC (1995) Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 155: 4078–4083PubMedGoogle Scholar
  32. Michel G, Kemény L, Homey B, Ruzicka T (1996) FK506 in the treatment of inflammatory skin disease: promises and perspectives Immunol Today 17: 106–108Google Scholar
  33. Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3: 55–7PubMedCrossRefGoogle Scholar
  34. Morison WL, Baughman RD, Day RM, Forbes PD, Hoenigsmann H, Krueger GG, Lebwohl M, Lew R, Naldi L, Parrish JA, Piepkorn M, Stern RS, Weinstein GD, Whitmore SE (1998) Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 134: 595–598PubMedCrossRefGoogle Scholar
  35. Mrowietz U, Christophers E, Altmeyer P (1999) Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 141: 424–429Google Scholar
  36. Mueller W, Hermann B (1976) Cyclosporin A for psoriasis. N Engl J Med 301: 355Google Scholar
  37. Nickoloff BJ, Karabin GD, Barker JNWN (1991) Localization of IL-8 and its inducer TNF-a in psoriasis. Am J Pathol 138: 129–140PubMedGoogle Scholar
  38. Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard P (1991) CD4 antibody treatment of severe psoriasis. Lancet 338: 321PubMedCrossRefGoogle Scholar
  39. Norlind R (1954) Significance of infections in origination of psoriasis. Acta Rheum Scand 1: 135–140CrossRefGoogle Scholar
  40. Nyfors A, Rasmussen PA, Lemholt K, Eriksen B (1975) Improvement of refractory psoriasis vulgaris after tonsillectomy. Dermatologica 151: 216–222PubMedCrossRefGoogle Scholar
  41. Oldstone MB (1987) Molecular mimicry and autoimmune disease. Cell 50: 819–820PubMedCrossRefGoogle Scholar
  42. Pinkus H, Mehregan AH (1966) The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Dermatol 46: 109–116PubMedGoogle Scholar
  43. Prinz JC, Braun-Falco O, Meurer M, Daddona P, Reiter C, Rieber EP, Riethmüller G (1991) Chimeric CD4 monoclonal antibody in the treatment of generalized pustular psoriasis. Lancet 338: 320–321PubMedCrossRefGoogle Scholar
  44. Prinz JC, Gross B, Vollmer S, Trommler P, Strobel I, Meurer M, Plewig G (1994) T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro. Eur J Immunol 24: 593–598PubMedCrossRefGoogle Scholar
  45. Prinz JC, Vollmer S, Boehncke W-H, Menssen A, Laisney I, Trommler P (1999) Selection of conserved TCR-VDJ-rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. Eur J Immunol 29: 3360–3368PubMedCrossRefGoogle Scholar
  46. Prodeus AP, Zhou X, Maurer M, Galli SJ, Carroll MC (1997) Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature 390: 172–175PubMedCrossRefGoogle Scholar
  47. Ragaz A, Ackerman AB (1979) Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol 1: 199–214Google Scholar
  48. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41: 401–407PubMedCrossRefGoogle Scholar
  49. Robinson JH, Kehoe MA (1992) Group A streptococcal M proteins: virulence factors and protective antigens. Immunol Today 13: 362–367PubMedCrossRefGoogle Scholar
  50. Roenigk HH, Jr., Auerbach R, Maibach H, Weinstein G, Lebwohl M (1998) Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 38: 478–485PubMedCrossRefGoogle Scholar
  51. Schaible UE, Collins HL, Kaufmann SH (1999) Confrontation between intracellular bacteria and the immune system. Adv Immunol 71: 267–377PubMedCrossRefGoogle Scholar
  52. Schmitt Egenolf M, Eiermann TH, Boehncke WH, Stander M, Sterry W (1996) Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57–DRB1*0701-DQA1’0201-DQB1“0303: a population-and family-based study. J Invest Dermatol 106: 711–714CrossRefGoogle Scholar
  53. Schröder JM, Harder J (1999) Human beta-defensin-2. Int J Biochem Cell Biol 31: 645–651PubMedCrossRefGoogle Scholar
  54. Shelley WB, Kirschbaum JO (1961) Generalized pustular psoriasis. Arch Dermatol 84: 73–78CrossRefGoogle Scholar
  55. Sigmundsdottir H, Sigurgeirsson B, Troye Blomberg M, Good MF, Valdimarsson H, Jonsdottir I (1997) Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. Scand J Immunol 45: 688–697PubMedCrossRefGoogle Scholar
  56. Tazi Ahnini R, Camp NJ, Cork MJ, Mee JB, Keohane SG, Duff GW, di Giovine FS (1999) Novel genetic association between the corneodesmosin ( MHC S) gene and susceptibility to psoriasis. Hum Mol Genet 8: 1135–1140Google Scholar
  57. Tervaert WC, Esseveld H (1970) A study of the incidence of haemolytic streptococci in the throat in patients with psoriasis vulgaris, with reference to their role in the pathogenesis of this disease. Dermatologica 140: 282–290PubMedCrossRefGoogle Scholar
  58. Valdimarsson H, Baker BS, Jonsdottir I, Fry L (1986) Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes Immunol Today 7: 256–259Google Scholar
  59. Valdimarsson H, Sigmundsdottir H, Jonsdottir I (1997) Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Clin Exp Immunol 107 Suppl 1: 21–24Google Scholar
  60. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz JC (1994) T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 24: 23772382Google Scholar
  61. Weinshenker BG, Bass BH, Ebers GC, Rice GP (1989) Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J Am Acad Dermatol 20: 1132–1133PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2001

Authors and Affiliations

  • Jörg Christoph Prinz

There are no affiliations available

Personalised recommendations